Clinical Outcomes and Molecular Biomarkers of Response to Pembrolizumab plus Fulvestrant in ER+/HER2− Metastatic Breast Cancer: Results from a Big Ten Cancer Research Consortium Multicenter Phase II Study

Nancy Chan, Dirk Moore, Nadia Baka, Kari Wisinski, Jairam Krisnamurthy, Jatin Rana, Pavan Tandra, Douglas Marks, Malinda West, Deimante Tamkus, Chunxia Chen, Yue Wang, Jacqueline Wang, Lisa Arendt, Kim M. Hirshfield, Mridula George, Shridar Ganesan, Deborah Toppmeyer, Coral Omene

Open source

DOI: 10.21203/rs.3.rs-11077127/v1
Published: 2026-10-23
Container: Not recorded
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 60/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
cautionPublication version: Identified as a preprint; peer review and later versions may change the record. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21203/rs.3.rs-11077127/v1,
  title = {Clinical Outcomes and Molecular Biomarkers of Response to Pembrolizumab plus Fulvestrant in ER+/HER2− Metastatic Breast Cancer: Results from a Big Ten Cancer Research Consortium Multicenter Phase II Study},
  author = {Nancy Chan and Dirk Moore and Nadia Baka and Kari Wisinski and Jairam Krisnamurthy and Jatin Rana and Pavan Tandra and Douglas Marks and Malinda West and Deimante Tamkus and Chunxia Chen and Yue Wang and Jacqueline Wang and Lisa Arendt and Kim M. Hirshfield and Mridula George and Shridar Ganesan and Deborah Toppmeyer and Coral Omene},
  year = {2026},
  doi = {10.21203/rs.3.rs-11077127/v1},
  url = {https://doi.org/10.21203/rs.3.rs-11077127/v1}
}

RIS

TY  - JOUR
TI  - Clinical Outcomes and Molecular Biomarkers of Response to Pembrolizumab plus Fulvestrant in ER+/HER2− Metastatic Breast Cancer: Results from a Big Ten Cancer Research Consortium Multicenter Phase II Study
AU  - Nancy Chan
AU  - Dirk Moore
AU  - Nadia Baka
AU  - Kari Wisinski
AU  - Jairam Krisnamurthy
AU  - Jatin Rana
AU  - Pavan Tandra
AU  - Douglas Marks
AU  - Malinda West
AU  - Deimante Tamkus
AU  - Chunxia Chen
AU  - Yue Wang
AU  - Jacqueline Wang
AU  - Lisa Arendt
AU  - Kim M. Hirshfield
AU  - Mridula George
AU  - Shridar Ganesan
AU  - Deborah Toppmeyer
AU  - Coral Omene
PY  - 2026
DO  - 10.21203/rs.3.rs-11077127/v1
UR  - https://doi.org/10.21203/rs.3.rs-11077127/v1
ER  -

APA

Chan, N., Moore, D., Baka, N., Wisinski, K., Krisnamurthy, J., Rana, J., Tandra, P., Marks, D., West, M., Tamkus, D., Chen, C., Wang, Y., Wang, J., Arendt, L., Hirshfield, K. M., George, M., Ganesan, S., Toppmeyer, D., & Omene, C. (2026). Clinical Outcomes and Molecular Biomarkers of Response to Pembrolizumab plus Fulvestrant in ER+/HER2− Metastatic Breast Cancer: Results from a Big Ten Cancer Research Consortium Multicenter Phase II Study. https://doi.org/10.21203/rs.3.rs-11077127/v1

Source records

crossref · retrieved 2026-11-10T14:13:32.143Z